We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Moves -1.36%: What You Should Know
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was down 1.36% at $14.54. This change was narrower than the S&P 500's daily loss of 2.71%. Meanwhile, the Dow lost 1.9%, and the Nasdaq, a tech-heavy index, lost 3.56%.
The infectious disease drug developer's shares have seen a decrease of 8.5% over the last month, not keeping up with the Medical sector's gain of 2.6% and the S&P 500's gain of 3.5%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company is expected to report EPS of $0.16, up 6.67% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $130.1 million, indicating a 8.56% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.57 per share and a revenue of $506.7 million, representing changes of +16.33% and +18.82%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 25.86. This expresses a premium compared to the average Forward P/E of 19.91 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Stock Moves -1.36%: What You Should Know
In the latest close session, Adma Biologics (ADMA - Free Report) was down 1.36% at $14.54. This change was narrower than the S&P 500's daily loss of 2.71%. Meanwhile, the Dow lost 1.9%, and the Nasdaq, a tech-heavy index, lost 3.56%.
The infectious disease drug developer's shares have seen a decrease of 8.5% over the last month, not keeping up with the Medical sector's gain of 2.6% and the S&P 500's gain of 3.5%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company is expected to report EPS of $0.16, up 6.67% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $130.1 million, indicating a 8.56% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.57 per share and a revenue of $506.7 million, representing changes of +16.33% and +18.82%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 25.86. This expresses a premium compared to the average Forward P/E of 19.91 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.